- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03027102
Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia
Phase I Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G2M9
- Princess Margaret Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Patient Inclusion Criteria:
- Patients with AML who are 18 years of age or older.
- Viably frozen cells from the time of diagnosis or relapse are available for sensitivity testing to DNT cells.
- Patients have given informed consent.
- Patients in remission following FLAG-Ida induction therapy who are receiving consolidation treatment.
- Creatinine < 1.5 x ULN within 7 days prior to day 1 of study treatment.
- AST, ALP, bilirubin < 1.5x ULN within 7 days prior to day 1 of study treatment.
Female patients of childbearing potential should be willing to use 2 methods of birth control (Refer to section 9.2.15 or be surgically sterile, or abstain from heterosexual activity for the course of the study from day 1 until 1 months following chemotherapy. Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 2 years.
Male patients should use condoms or abstain from sex from the time of beginning chemotherapy to 1 month after the chemotherapy.
- Patients must be able to comply with study procedures, at the minimum, until all DNT-UHN-1 cells are out of their system.
Patient Exclusion Criteria:
- ECOG performance status <2.
- Patients with a known persistent infection.
- Patients with known active CNS disease.
- Life expectancy < 3 months.
- Patients should be off Cox2 inhibitors and corticosteroids for at least 3 days prior to and 7 days after infusion of DNT cells.
- Patients who are HIV positive.
- Patients for whom healthy donor DNT kill <10% of patient's blast cells.
Donor Inclusion Criteria:
- Has given written informed consent.
- Is 18 years of age or older.
- No known prior blood product transfusion or surgery.
- Blood electrolytes (Sodium, Potassium, Chloride, Bicarbonate, Magnesium, Phosphate, Calcium) within normal ranges.
- Normal complete blood counts.
- Normal liver and kidney function (Bilirubin, AST, ALT, ALP, LDH, plasma albumin, creatinine).
- Negative for transfusion transmissible illnesses (CMV, HIV I/II, HTLV I/II, Hepatitis B Surface Antigen, Hepatitis B Surface Antibody, Hepatitis B Core Antibody, Hepatitis C Antibody) within 30 days of blood collection for DNT cell expansion for patient infusion.
- Negative for evidence of exposure to West Nile Virus, Syphilis within 30 days of blood collection for DNT cell expansion for patient infusion.
- DNT cell expansion yield is >108 per mL blood using the standard protocol. Expanded DNT cells show ≥20% cytotoxicity to at least 3 AML cell lines (MV4-11 AML3, and U937).
- The donor who meet all donor inclusion/exclusion criteria, whose DNT cells show the most potent killing (minimum >10% killing) of AML patient's blast cells (blast cells frozen at time of diagnosis or relapse) will be approached for participation in this study.
Donor Exclusion Criteria:
- With a history of high risk behavior including, but not limited to, a history of piercing (except ear lobes), tattoos or other body modification.
- Has serious illnesses such as cardiovascular disease & cancer.
- Has sexually transmissible disease.
- Has history of intravenous drug use.
- Persons who received any vaccinations in past 3 months prior to enrolment into this study.
- Persons who travel outside the U.S. and Canada in the past 3 years prior to enrolment into this study, to areas that are considered endemic for malaria.
- Persons who have received blood components or other human tissues in the past 12 months prior to enrolment into this study (however this may be reduced to 6 months if nucleic acid testing (NAT) is used for the tests).
- Pregnant or lactating.
- Persons at risk of transmitting a hematological or immunological disease.
- Persons with transmissible genetic diseases in the family.
- On prescription medication.
- Persons with prion-related disease.
- Persons with a neurological disease of an unestablished etiology.
- Persons with active encephalitis or meningitis of infectious or unknown etiology.
- Persons with rabies or persons who, within the past 6 months, were bitten by an animal and treated as if the animal was rabid.
- Persons with a family history of Creutzfeldt-Jakob disease.
- Persons who have received human-derived pituitary growth hormone or dura mata.
- Persons who have known or suspected sepsis at the time of donation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patient Arm
Patients will receive DNT cells from healthy donors.
|
DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
|
No Intervention: Donor Arm
Healthy volunteer donors will donate blood.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adverse events and abnormal laboratory studies.
Time Frame: 2 years
|
Patients will be assessed for adverse events based upon, but not limited to, monitoring of vital signs and prescribed laboratory studies.
Adverse events (AE) will use the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE).
This study will utilize the CTCAE Version 4.03 for adverse event reporting.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of cells with disease specific mutations per patient
Time Frame: 2 years
|
Quantitive real time polymerase chain reaction (PCR) analysis for disease specific mutations will be performed on the bone marrow aspirate.
|
2 years
|
Leukemia load
Time Frame: 2 years
|
Peripheral blood will be obtained after DNT cell infusion to monitor leukemia load and residual disease by determining the frequency of leukemic cell markers on cells using flow cytometry.
|
2 years
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OZM-079
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
Clinical Trials on DNT cells
-
Guangdong Ruishun Biotech Co., LtdAnhui Provincial HospitalRecruitingAcute Myeloid LeukemiaChina
-
Guangdong Ruishun Biotech Co., LtdFirst Affiliated Hospital of Zhejiang UniversityRecruiting
-
Second Affiliated Hospital, School of Medicine,...Zhejiang Ruijiamei Biotechnologies, Co., Ltd.RecruitingB-cell Non-Hodgkin's LymphomaChina
-
Guangdong Ruishun Biotech Co., LtdRuijin Hospital; Southern Medical University, China; Beijing GoBroad HospitalNot yet recruitingB-cell Non-Hodgkin's Lymphoma
-
Yale UniversityRecruitingDepression | Quality of Life | CognitionUnited States
-
Guangdong Ruishun Biotech Co., LtdChanghai Hospital; Peking University People's Hospital; RenJi Hospital; The Affiliated...Not yet recruitingSystemic Lupus ErythematosusChina
-
RenJi HospitalGuangdong Ruishun Biotech Co., LtdRecruitingSystemic Lupus Erythematosus | Systemic Sclerosis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Idiopathic Inflammatory MyopathiesChina
-
Medical College of WisconsinMiltenyi Biomedicine GmbHActive, not recruitingB-cell Chronic Lymphocytic Leukemia | B-cell Non Hodgkin LymphomaUnited States
-
University College, LondonUnknownTendinopathy | Achilles Tendinitis | Achilles Degeneration | Achilles Tendinitis, Right Leg | Achilles Tendon Thickening | Achilles Tendinitis, Left LegUnited Kingdom
-
Chongqing Public Health Medical CenterZhejiang Qixin Biotech; Chongqing Sidemu BiotechUnknown